简讯：云顶新耀达成重大独家商业化许可协议 新药申请获批

Group 1 - Company announced an exclusive commercialization agreement with Maikouote for the new drug MT1013, aimed at treating secondary hyperparathyroidism (SHPT), with a transaction value of up to 1.24 billion RMB (179 million USD) [2] - The agreement includes an upfront payment of 200 million RMB and potential milestone payments of up to 1.04 billion RMB, with ongoing Phase III clinical trials funded by Maikouote [2] - The company also received approval from the National Medical Products Administration of China for its drug Velsipity, which treats moderate to severe active ulcerative colitis (UC) in adults who do not respond adequately to traditional treatments [2][3] Group 2 - Velsipity is a new generation high-selectivity S1P receptor modulator, approved based on two Phase III studies demonstrating statistical significance and clinical relevance across all primary and secondary efficacy endpoints [3] - Following these announcements, the company's stock price increased by 5.5% over two trading days, with a year-to-date increase of 7.2% [4]